GAITHERSBURG, Md. (AP) — A Maryland pharmaceutical company will acquire the maker of the opioid overdose reversal nasal spray Narcan.
The Baltimore Sun reports Emergent Solutions has agreed to pay $735 million in cash and stock to Ireland-based Adapt Pharma. CEO Daniel J. Abdun-Nabi said in a Wednesday statement the widely used drug aligns with Emergent's position "to protect and enhance life."
The federal government has declared the opioid epidemic a public health emergency that's claimed thousands of lives.
Narcan is the only approved nasal spray version of naxolone, costing $150 for two doses. While public health programs can negotiate lower prices, access and affordability remains an issue.
Emergent's Doug White says the company plans to invest in addiction and overdose drugs and work with federal officials to ensure grants to offset costs.
___
This article has been corrected to fix the spelling of Doug White's first name.
___
Information from: The Baltimore Sun, http://www.baltimoresun.com
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report